Addiction to substances such as alcohol, cocaine, opioids, and methamphetamine poses a continuing clinical and public challenge globally. Despite progress in understanding substance use disorders, challenges remain in their treatment. Some of these challenges include limited ability of therapeutics to reach the brain (blood-brain barrier), adverse systemic side effects of current medications, and importantly key aspects of addiction not addressed by currently available treatments (such as cognitive impairment). Inability to sustain abstinence or seek treatment due to cognitive deficits such as poor decision-making and impulsivity is known to cause poor treatment outcomes. In this review, we provide an evidenced-based rationale for intranasal drug delivery as a viable and safe treatment modality to bypass the blood-brain barrier and target insulin to the brain to improve the treatment of addiction. Intranasal insulin with improvement of brain cell energy and glucose metabolism, stress hormone reduction, and improved monoamine transmission may be an ideal approach for treating multiple domains of addiction including memory and impulsivity. This may provide additional benefits to enhance current treatment approaches.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007475 | PMC |
| http://dx.doi.org/10.1007/s13311-019-00822-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal insulin administration affecting perioperative neurocognitive dysfunction by regulating calcium transport protein complex IP3R/GRP75/VDAC1 on MAMs.
Free Radic Biol Med
January 2025
Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, China. Electronic address:
Unlabelled: Perioperative neurocognitive disorders (PND) are common complications following surgery and anesthesia, especially in the elderly. These disorders are associated with disruptions in neuronal energy metabolism and mitochondrial function. This study explores the potential of intranasal insulin administration as a therapeutic strategy to prevent PND by targeting the calcium transport protein complex IP3R/GRP75/VDAC1 on mitochondria-associated endoplasmic reticulum membranes (MAMs).
View Article and Find Full Text PDFLaminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study.
IEEE J Transl Eng Health Med
December 2024
Rocket Science Health Victoria BC V8V 2Y1 Canada.
Focal intranasal drug delivery to the olfactory cleft is a promising avenue for pharmaceuticals targeting the brain. However, traditional nasal sprays often fail to deliver enough medication to this specific area. We present a laminar fluid ejection (LFE) method for precise delivery of medications to the olfactory cleft.
View Article and Find Full Text PDFIntranasal insulin increases brain glutathione (GSH) and enhances antioxidant capacity in healthy participants, but not in those with early psychotic disorders.
Biol Psychiatry Cogn Neurosci Neuroimaging
November 2024
Psychotic Disorders Division, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- * Twenty-one patients and 18 controls underwent pre- and post-insulin cognitive and magnetic resonance spectroscopy (MRS) assessments to measure changes in brain metabolites.
- * Results showed that while intranasal insulin increased glutathione levels and improved cognitive performance in healthy participants, it did not have the same effect in individuals with early psychotic disorders.
Transmucosal glucagon rapidly increases blood glucose concentration in healthy cats.
J Feline Med Surg
November 2024
Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, FL, USA.
Objectives: To evaluate the effect of transmucosal glucagon powder (Baqsimi; Amphastar Pharmaceuticals) on blood glucose (BG) concentrations in healthy cats and describe adverse reactions to its administration.
Methods: A randomized, controlled, crossover study was conducted on six healthy cats with a 7-day washout period between treatments. Transmucosal glucagon powder was administered intranasally and rectally and compared with intranasal placebo.
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
J Alzheimers Dis
November 2024
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.
Background: Insulin-like growth factor-1 (IGF-1) promotes neurogenesis, cell survival, and glial function, making it a promising candidate therapy in Alzheimer's disease (AD).
Objective: Long arginine 3-IGF-1 (LR3-IGF-1) is a potent IGF-1 analogue. We sought to determine whether intranasal (IN) LR3 treatment would delay cognitive decline and pathology in 5XFAD mice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!